Halozyme Therapeutics reported $103.28M in Stock for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Stock Change
Acadia Pharmaceuticals ACAD:US USD 5.84M 483K
Agios Pharmaceuticals AGIO:US USD 5.18M 1.12M
Alnylam Pharmaceuticals ALNY:US USD 115.49M 26.51M
Amarin AMRN:US USD 227.61M 1.83M
Amgen AMGN:US USD 4.76B 203M
Baxter International BAX:US USD 2.68B 12M
Cara Therapeutics CARA:US USD 1.84M 1.62M
Eli Lilly And LLY:US USD 3.83B 68.3M
Esperion Therapeutics ESPR:US USD 29.54M 313K
Halozyme Therapeutics HALO:US USD 103.28M 5.66M
Intra Cellular Therapies ITCI:US USD 23.6M 1.42M
Intrexon XON:US USD 219K 5K
JAZZ PHA JAZZ:US USD 728.07M 133.63M
Mannkind MNKD:US USD 18.27M 2.3M
Nektar Therapeutics NKTR:US USD 19.06M 2.09M
Peregrine Pharmaceuticals PPHM:US USD 39.06M 8.71M
Rigel Pharmaceuticals RIGL:US USD 7.12M 898K
United Therapeutics UTHR:US USD 91M 1.1M
Vanda Pharmaceuticals VNDA:US USD 1.59M 94K